Expertise in
7
conditions

Hui J. Zhou

87 Xiangya Rd, 
Changsha, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
87 Xiangya Rd, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Hui Zhou practices in Changsha, China. Ms. Zhou is highly rated in 7 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Sleeve Gastrectomy, and Gastrectomy.

Her clinical research consists of co-authoring 269 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

87 Xiangya Rd, Changsha, China
Other Locations
87 Xiangya Road, Changsha, 410000, China
No. 107, West Yan Jiang Road, Guangzhou, 510120, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2025
Intervention Type: Drug
Study Drug: LOXO-305
Study Phase: Phase 2
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: ATG-010
Study Phase: Phase 2
A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematological Malignancies
A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematological Malignancies
Enrollment Status: Completed
Publish Date: November 13, 2024
Intervention Type: Drug
Study Drug: ZX-101A
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib SandwichWith Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma
An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib SandwichWith Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug
Study Drug: Sintilimab
Study Phase: Phase 2
A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
A Phase II, Multicenter, Open, Single-arm Study of TQB2450 Injection (PD-L1 Antibody) in Subjects With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 2 Study
P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 2 Study
Enrollment Status: Unknown
Publish Date: January 28, 2020
Intervention Type: Drug, Radiation
Study Drugs: PEG-Aspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study Phase: Phase 2
View 8 Less Clinical Trials

269 Total Publications

Survival outcomes and failure patterns in stage I/II extranodal NK/T-cell lymphoma after involved site radiotherapy with asparaginase-based chemotherapy-a retrospective study.
Survival outcomes and failure patterns in stage I/II extranodal NK/T-cell lymphoma after involved site radiotherapy with asparaginase-based chemotherapy-a retrospective study.
Journal: Leukemia & lymphoma
Published: December 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zhou's expertise for a condition
ConditionClose
    View All 65 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile